Aug 5, 2021 · Lung squamous cell carcinoma (LSCC) remains a leading cause of cancer death with few therapeutic options. We characterized the proteogenomic landscape of LSCC, providing a deeper exposition of LSCC biology with potential therapeutic implications.

Feb 28, 2023 · Lung squamous cell carcinoma (LSCC), also called squamous cell lung cancer, is one of the major subtypes of non-small cell lung cancer (NSCLC). Fifty years ago, LSCC was the most common lung cancer diagnosis.

Studies have highlighted the importance of USP28 in controlling various cancers, including gliomas, bowel cancer, and breast cancer, suggesting its potential as a novel therapeutic target for LSCC (143–145).

Mar 14, 2020 · Lung cancer has the highest prevalence among all malignancies, and is the leading cancer killer in both men and women worldwide. About 85% to 90% of lung cancers are non-small cell lung cancer (NSCLC), of which lung squamous cell carcinoma (LSCC) accounts for about 30% of all cases of NSCLC ( 1 ).

Feb 28, 2023 · Lung squamous cell carcinoma (LSCC), also called squamous cell lung cancer, is one of the major subtypes of non-small cell lung cancer (NSCLC). Fifty years ago, LSCC was the most common lung cancer diagnosis.

Aug 5, 2021 · Lung squamous cell carcinoma (LSCC) remains a leading cause of cancer death with few therapeutic options. We characterized the proteogenomic landscape of LSCC, providing a deeper exposition of LSCC biology with potential therapeutic implications.

Oct 5, 2022 · Lung cancer is the leading cause of cancer-related death across the world. Unlike lung adenocarcinoma, patients with lung squamous cell carcinoma (LSCC) have not benefitted from targeted...

Apr 5, 2024 · Radiology and pathology images from CPTAC patients are being collected and made publicly available by The Cancer Imaging Archive to enable researchers to investigate cancer phenotypes which may correlate to corresponding proteomic, genomic and clinical data.

Lung squamous cell carcinoma (LSCC) is the second most common pathological type of lung cancer, second to lung adenocarcinoma. LSCC accounts for 40%-50% of all lung cancer cases, and its early symptoms are not obvious and atypical; thus, most patients are already at a middle or late stage by the time of diagnosis . In recent years, advances in ...

Feb 9, 2021 · Proposed model on how amplified TNIK contributes to LSCC progression. CCR researchers have identified the protein kinase TNIK as a therapeutic target for lung squamous cell carcinoma (LSCC), the second most common type of lung cancer.